Read this company snapshot
Daily valuation snapshot
Eupraxia Pharmaceuticals Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $7.46
- Market capitalization (USD)
- $492,907,362.58
- Price / earnings (TTM)
- Not reported
- Price / book
- 6.13
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research EPRX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research EPRX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing EPRX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $7.46 |
| Market capitalization (USD) | $492,907,362.58 |
| Price / earnings (TTM) | Not reported |
| Price / book | 6.13 |
No matching rows. Clear the filter to see all records.
Read EPRX's valuation metrics
Company size
Eupraxia Pharmaceuticals Inc. Common Stock's recorded market capitalization is $492,907,362.58. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
EPRX's recorded price-to-book ratio is 6.13. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Eupraxia Pharmaceuticals Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about EPRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow EPRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.